Table 5: Genes associated with effector T cells activation and cytokines involved in T-cell-mediated immunity.

symbolGenBank accessionGene descriptionlog2 FCa
M/NSH/MSM/MSL/MOseltamivir/M

Gzmb PH_mM_0001308Granzyme B4.361.17−4.79−0.13−1.54
Prf1 mMC017608Perforin 12.430.31−2.71−0.55−1.55
Fas mMC008894 Tumor necrosis factor receptor superfamily member 61.70 −1.13 −1.83 −0.88 −1.70
FasL mMC013655Fas ligand1.91−1.49−2.13−0.08−1.07
Il4 PH_mM_0000958Interleukin 4, IL-4 5.43−1.00−5.19−1.33−2.64
Ifng PH_mM_0001407Interferon-gamma, IFN-γ−1.021.281.231.381.35

The intensity ratio of probe signal criteria for differential expressions was defined as a twofold change (up or down) (log2 ratio ≥ 1 or ≤−1) in gene expression compared with virus control group and a value less than 0.05 in at least one time point as a minimum requirement to select. For instance, log2 (M/N) ≥ 1 means that the comparison between normal control group and virus control group was scattered, indicating that a large number of genes in virus control group were up-regulated in response to H1N1 infection. log2 (SH/M) ≤ −1, log2 (SM/M) ≤ −1, log2 (SL/M) ≤ −1, and log2 (Oseltamivir/M) ≤ −1 means that down-regulation in gene expression attributable to the high-dose SFXF group treatment, medium-dose SFXF group treatment, low-dose SFXF group treatment, and Oseltamivir group treatment was done by comparing genes in virus control group, respectively ( value data not shown).